SG10201702828TA - Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof - Google Patents

Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof

Info

Publication number
SG10201702828TA
SG10201702828TA SG10201702828TA SG10201702828TA SG10201702828TA SG 10201702828T A SG10201702828T A SG 10201702828TA SG 10201702828T A SG10201702828T A SG 10201702828TA SG 10201702828T A SG10201702828T A SG 10201702828TA SG 10201702828T A SG10201702828T A SG 10201702828TA
Authority
SG
Singapore
Prior art keywords
symptoms associated
behavioral
prophylactic
salt
therapeutic agent
Prior art date
Application number
SG10201702828TA
Other languages
English (en)
Inventor
Shinji Sato
Kenji Maeda
Dai Ishikawa
Mai Nakamura
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG10201702828TA publication Critical patent/SG10201702828TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
SG10201702828TA 2012-10-25 2013-10-24 Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof SG10201702828TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261718305P 2012-10-25 2012-10-25
US201361782467P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
SG10201702828TA true SG10201702828TA (en) 2017-05-30

Family

ID=49585556

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201702828TA SG10201702828TA (en) 2012-10-25 2013-10-24 Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
SG11201503152TA SG11201503152TA (en) 2012-10-25 2013-10-24 Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201503152TA SG11201503152TA (en) 2012-10-25 2013-10-24 Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof

Country Status (22)

Country Link
US (4) US20150272946A1 (ja)
EP (2) EP3848033A1 (ja)
JP (5) JP6329140B2 (ja)
KR (1) KR102245016B1 (ja)
CN (4) CN108578408A (ja)
AR (1) AR093247A1 (ja)
AU (1) AU2013335613B2 (ja)
BR (1) BR112015008759A2 (ja)
CA (1) CA2889196C (ja)
EA (1) EA201590808A1 (ja)
HK (1) HK1212609A1 (ja)
IL (1) IL238402B (ja)
JO (2) JOP20210047A1 (ja)
MX (1) MX371279B (ja)
MY (1) MY180185A (ja)
NZ (1) NZ708321A (ja)
PH (1) PH12015500925B1 (ja)
SG (2) SG10201702828TA (ja)
TW (1) TWI643620B (ja)
UA (1) UA116549C2 (ja)
WO (1) WO2014065437A1 (ja)
ZA (1) ZA201503640B (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
PT2364142T (pt) 2008-10-28 2018-04-23 Arena Pharm Inc Composições de um modulador do recetor da serotonina 5-ht2a para o tratamento de distúrbios com ele relacionados
WO2015163486A1 (en) * 2014-04-22 2015-10-29 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
WO2016115144A1 (en) * 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating alzheimer's disease
CN107206006A (zh) * 2015-01-12 2017-09-26 雷维瓦药品公司 用于治疗与帕金森病相关联的精神病的方法
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
CN105175401A (zh) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 一种依匹哌唑的制备方法
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
JPWO2021029020A1 (ja) * 2019-08-13 2021-02-18
US20230106974A1 (en) * 2020-06-24 2023-04-06 National University Corporation Hokkaido University Agent for protection of blood brain spinal cord barrier
CN112137994B (zh) * 2020-09-15 2022-10-14 中山大学 小分子化合物在制备抗丝状病毒药物中的应用
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN115429753B (zh) * 2021-06-02 2024-08-06 山东百诺医药股份有限公司 布瑞哌唑口服混悬液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
AR085840A1 (es) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
EP2822136B1 (en) * 2013-07-03 2018-08-29 Siemens Aktiengesellschaft Method and arrangement for transferring electrical power for subsea applications

Also Published As

Publication number Publication date
KR102245016B1 (ko) 2021-04-26
AR093247A1 (es) 2015-05-27
CN114712360A (zh) 2022-07-08
JOP20210047A1 (ar) 2017-06-16
IL238402B (en) 2018-11-29
ZA201503640B (en) 2016-08-31
CN104755082A (zh) 2015-07-01
IL238402A0 (en) 2015-06-30
SG11201503152TA (en) 2015-05-28
EA201590808A1 (ru) 2015-08-31
HK1212609A1 (zh) 2016-06-17
TWI643620B (zh) 2018-12-11
TW201427665A (zh) 2014-07-16
EP3848033A1 (en) 2021-07-14
US20190314367A1 (en) 2019-10-17
MY180185A (en) 2020-11-24
JP6329140B2 (ja) 2018-05-23
KR20150074156A (ko) 2015-07-01
CN112402421A (zh) 2021-02-26
JP2018138555A (ja) 2018-09-06
CN108578408A (zh) 2018-09-28
BR112015008759A2 (pt) 2017-07-04
CA2889196A1 (en) 2014-05-01
US20220370442A1 (en) 2022-11-24
US20170258787A1 (en) 2017-09-14
AU2013335613B2 (en) 2018-07-12
EP2911670A1 (en) 2015-09-02
JP2015535211A (ja) 2015-12-10
UA116549C2 (uk) 2018-04-10
PH12015500925A1 (en) 2015-06-29
JOP20130313B1 (ar) 2021-08-17
MX371279B (es) 2020-01-24
PH12015500925B1 (en) 2015-06-29
US20150272946A1 (en) 2015-10-01
WO2014065437A1 (en) 2014-05-01
AU2013335613A1 (en) 2015-06-04
NZ708321A (en) 2019-03-29
CA2889196C (en) 2021-02-16
JP2021181448A (ja) 2021-11-25
JP2023123441A (ja) 2023-09-05
JP2020045345A (ja) 2020-03-26
MX2015005174A (es) 2015-09-04

Similar Documents

Publication Publication Date Title
HK1212609A1 (zh) 含有依匹唑派或其鹽的用於與神經變性疾病相關的行為和精神症狀或與精神疾病相關的衝動症狀的預防和/或治療劑
IL274988A (en) Carbamoylpyridone-polycyclic compounds and their pharmaceutical use
HK1207990A1 (en) Tetrahydronaphthyridine and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease ror
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
HK1203977A1 (en) Enhancement of transport of therapeutic molecules across the blood brain barrier
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
EP2856421A4 (en) SYSTEMS AND METHODS FOR TRANSPARENT MEDICAL TREATMENT DELIVERY
HUS2000020I1 (hu) Ciklezonid a légúti betegségek kezelésére lovaknál
IL232824A0 (en) Medical and/or diagnostic nanocarriers targeting mmp
ZA201603118B (en) Compounds for use in prevention and treatment of neurodegenerative diseases and pain
GB201322302D0 (en) Back scattering inspection system for human body
EP2903436A4 (en) HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE NEURODAURATIVE
HK1218882A1 (zh) 用於治療神經退化疾病和其它疾病的組合治療劑和方法
GB201317550D0 (en) Use of Enalaprilat for treatment of neurodegenerative diseases